A Pilot Study Evaluating the Efficacy of the Vielight Neuro RX Gamma in the Treatment of Post COVID-19 Cognitive Impairment

Launched by VIELIGHT INC. · May 10, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring the effectiveness of a device called the Vielight Neuro RX Gamma in helping people recover from cognitive issues that can occur after a COVID-19 infection, often referred to as post COVID-19 cognitive impairment or long COVID. Many people experience symptoms such as brain fog, confusion, and fatigue long after recovering from the virus. The Vielight device uses a specific type of light therapy aimed at supporting brain function and reducing inflammation, which may help alleviate these lingering symptoms.

To participate in the study, individuals must be between 18 and 65 years old and have been diagnosed with post COVID cognitive impairment. Participants will be randomly assigned to either receive the actual Vielight treatment or a placebo (a dummy treatment that doesn’t have any real effect) for 120 days. Throughout the trial, participants will fill out daily surveys to track their symptoms. The trial will be conducted online, making it easy for participants to take part from home. This study aims to better understand how this light therapy might benefit those struggling with cognitive challenges after COVID-19.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female age 18-65.
• • Diagnosed with Post COVID cognitive impairment who meets WHO-defined post-COVID-19 condition
• • Mini Mental State Examination (MMSE) score of \<27
• • Capable of filling out an online patient diary in English.
• Exclusion Criteria:
• • Current symptoms are explained by a psychiatric or neurological disorder
• • Having or history of any major neurological or psychiatric illness
• • Pregnant
• • Physical, cognitive, or language impairments sufficient to adversely affect data derived from cognitive assessments or History of mild traumatic brain injury (TBI)